3D Systems (DDD) Has Dropped 25.7% Since Previous Earnings Report: Is a Recovery Possible?
3D Systems Stock Performance Since Last Earnings
Approximately one month has passed since the previous earnings announcement from 3D Systems (DDD). During this period, the company's shares have dropped by 25.7%, lagging behind the S&P 500 index.
Will the Downtrend Persist?
As the next earnings report approaches, investors are wondering whether the recent decline will continue or if 3D Systems is poised for a turnaround. Before examining market reactions, let's review the latest financial results to better understand the factors at play.
Q4 Financial Highlights: Reduced Losses and Revenue Growth
For the fourth quarter of 2025, 3D Systems reported a non-GAAP loss of $0.13 per share, an improvement over the $0.19 per share loss from the same quarter last year. The consensus estimate from Zacks was a loss of $0.11 per share.
Total revenue reached $106.3 million, representing a 4.3% decrease year-over-year but a 16% increase compared to the previous quarter. Revenue surpassed the Zacks Consensus Estimate by nearly 8%.
Quarterly Segment Breakdown
- Product Revenue: Fell 11.2% year-over-year to $62.6 million, making up 59% of total revenue.
- Services Revenue: Rose 7.7% year-over-year to $43.7 million, accounting for 41% of total revenue.
The company operates two main divisions: Healthcare Solutions and Industrial Solutions. Healthcare Solutions covers dental, medical devices, personalized health, and regenerative medicine. Industrial Solutions serves sectors such as aerospace, defense, transportation, and manufacturing.
- Healthcare Solutions: Revenue grew 25% year-over-year to $50.5 million. MedTech saw an increase of over 8%.
- Industrial Solutions: Revenue declined 21.1% year-over-year to $55.8 million. However, Aerospace and Defense revenue jumped 50% compared to last year.
Operating Metrics for Q4
Non-GAAP gross profit for the quarter was $33 million, a 5% decrease from the previous year. The gross profit margin narrowed by 0.3 percentage points to 31%, mainly due to lower sales volumes.
Adjusted EBITDA loss was $5.3 million, significantly less than the $19.1 million loss reported a year earlier. Operating expenses on a non-GAAP basis were $42.5 million, down from $58.4 million in the prior year.
Balance Sheet Overview
As of December 31, 2025, 3D Systems held $97.1 million in cash and equivalents, up from $95.5 million at the end of September 2025.
Total debt stood at $90.3 million. Of this, $3.9 million is due in Q4 2026, while the remaining $92 million matures in 2030.
Q1 2026 Guidance
For the first quarter of 2026, 3D Systems anticipates revenue between $91 million and $94 million. Adjusted EBITDA loss is projected to range from $5 million to $3 million.
Estimate Trends Since Earnings
Following the earnings release, analyst estimates have generally moved upward. However, the consensus estimate has shifted by -22.73% as a result of these revisions.
VGM Score Analysis
Currently, 3D Systems holds a Growth Score of C and a Momentum Score of C. The Value Score is D, placing the stock in the lower 40% for this investment approach. The overall VGM Score is D, which may be most relevant for investors not focused on a single strategy.
Future Outlook
Although estimate revisions have been positive, the overall impact has been neutral. 3D Systems is assigned a Zacks Rank #4 (Sell), and expectations are for below-average performance in the coming months.
Top Stock Picks from Zacks
Zacks' research team has identified five stocks with strong potential to double in value. Among these, Director of Research Sheraz Mian highlights a satellite communications company poised for significant growth. As the space industry expands toward a trillion-dollar market, this firm's customer base is rapidly increasing, and analysts predict a substantial revenue surge in 2025. While not all picks are guaranteed winners, this selection could outperform previous Zacks picks such as Hims & Hers Health, which saw gains of over 200%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
RxERP's Hub: The Absence of a Central "Source of Truth" in Pharma Supply Chains May Lead to a Data Monopoly

CEA Industries Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Grupo Cibest S.A. ANNOUNCES FILING OF THE 2025 ANNUAL REPORT ON FORM 20-F

Identifying the Impact of Tariffs on Consumer Prices Instantly
